Recruiting
Phase 2

Nivolumab & 177Lu-girentuximab

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT05239533

Conditions

Clear Cell Renal Cell Carcinoma

Kidney Cancer

Advanced Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

177Lu-labeled-girentuximab

Nivolumab

89Zr-girentuximab PET/CT

177Lu whole body (WB) planar and SPECT/CT scans

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2025-05-18.